Levocarnitine to protect the liver during ALL chemotherapy
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests whether levocarnitine can reduce liver injury from a chemotherapy medicine called asparaginase in people with high-risk acute lymphoblastic leukemia (ALL). If you’re eligible, you would take levocarnitine by mouth alongside your planned standard cancer treatment to see if the liver stays healthier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 5 up to younger than 30 years
- Newly diagnosed with high-risk ALL
- Starting ALL treatment using a Children’s Oncology Group (COG) protocol
- Able to take pills by mouth and willing to follow the levocarnitine schedule
- No known allergy to levocarnitine or its ingredients
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
This trial tests if a medication can protect the liver during chemotherapy for children and teenagers newly diagnosed with acute lymphoblastic leukemia (ALL). It aims to reduce liver damage caused by treatment.
This trial tests whether taking the antibiotic levofloxacin can prevent a first serious infection (febrile neutropenia) in children with ALL during the first weeks of chemotherapy. It aims to keep kids safer during treatment.
This Phase 1 study looks at a treatment approach for people newly diagnosed with Philadelphia-negative B- or T-cell acute lymphoblastic leukemia (ALL) after completing a specific chemotherapy course called Hyper-CVAD 1A. It aims to see if the treatment can be given safely and how well it may work for this type of leukemia.
This study tests whether a supplement called levocarnitine can help reduce the amount of anemia medicine (ESA) you need. It is for people on dialysis who have anemia from kidney disease.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.